Know Cancer

forgot password

A Phase II Study of Bevacizumab Alone or in Combination With TRC105 for Advanced Renal Cell Cancer

Phase 2
18 Years
Open (Enrolling)
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer, Type 1 Papillary Renal Cell Carcinoma, Type 2 Papillary Renal Cell Carcinoma

Thank you

Trial Information

A Phase II Study of Bevacizumab Alone or in Combination With TRC105 for Advanced Renal Cell Cancer


I. To compare the progression-free survival at 12 and 24 weeks for bevacizumab alone or in
combination with TRC105 (anti-endoglin monoclonal antibody TRC105).


I. Toxicity and Response Evaluation Criteria in Solid Tumors (RECIST) response rate for the
combination compared to single agent bevacizumab.


I. To evaluate tumor tissue expression of endoglin (CD105), transforming growth factor, beta
receptor II (TGFBR2), activin A receptor type II-like 1 (ACVRL1) and transforming growth
factor, beta receptor 1 (TGFBR1) kinase from pre- and post-treatment tissue samples in order
to determine whether CD105 and stem cell activation occurs after exposure to anti-vascular
endothelial growth factor (VEGF) therapy as predicted by laboratory models, and whether
exposure to anti-endoglin monoclonal antibody TRC105 affects these changes.

II. A primary goal of tissue analysis will be to generate preliminary data to correlate
levels of CD105, TGFBR2, ACVRL1 and TGFBR1 in tissue with response to bevacizumab in
combination with anti-endoglin monoclonal antibody TRC105 compared to bevacizumab alone.

III. To compare the soluble CD105 levels at baseline and after treatment between the group
receiving bevacizumab alone and the group receiving bevacizumab in combination with
anti-endoglin monoclonal antibody TRC105.

IV. To compare TGFBR2 levels at baseline and after treatment between the group receiving
bevacizumab alone and the group receiving bevacizumab in combination with anti-endoglin
monoclonal antibody TRC105.

V. To evaluate whether circulating tumor cells (CTCs) can be detected in this patient
population using parylene membrane filter technology, and whether changes in CTC counts and
CD105 expression on CTCs during therapy correspond to imaging and clinical response.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive bevacizumab intravenously (IV) over 30-90 minutes on days 1 and 15.

ARM II: Patients receive bevacizumab as in arm 1 and anti-endoglin monoclonal antibody
TRC105 IV over 1-4 hours on days 1, 8, 15, and 22.

In both arms, treatment repeats every 28 days for up to 12 courses in the absence of disease
progression or unacceptable toxicity.

After completion of study therapy, patients are followed for 4 weeks.

Inclusion Criteria:

- Patients must have histologically or cytologically confirmed renal cancer; all
histologic subtypes will be eligible

- Patients must have metastatic disease which is measurable, defined as at least one
lesion that can be accurately measured in at least one dimension (longest diameter to
be recorded for non-nodal lesions and short axis for nodal lesions) to >= 20 mm in
the long axis by chest x-ray, >= 10 mm in the long axis by spiral computed tomography
(CT), magnetic resonance imaging (MRI), calipers, or clinical exam, or >= 15 mm in
the short axis for lymph nodes

- Patients must have received at least 1 prior systemic therapy for renal cancer but no
more than 3 prior therapies; they must have documented intolerance to or progression
despite at least 1 systemic therapy; therapy administered in the adjuvant setting
counts toward the prior systemic therapy total; if adjuvant therapy is the patient's
only prior therapy the disease must have recurred during treatment or within 3 months
of discontinuation

- Allowable prior therapies include VEGF tyrosine kinase inhibitor (TKIs), mammalian
target of rapamycin (mTOR) inhibitors, and cytokine therapy (example: interleukin-2

- At least 2 weeks must have elapsed from the last dose of the prior systemic therapy
for biologics and 4 weeks for chemotherapy (6 weeks for nitrosoureas or mitomycin C);
also note that at least 3 weeks should have elapsed since prior TKI administration

- Eastern Cooperative Oncology Group (ECOG) performance status =< 2

- Life expectancy of greater than 6 months

- Leukocytes >= 3,000/mcL

- Absolute neutrophil count >= 1,500/mcL

- Platelets >= 100,000/mcL

- Total bilirubin within normal institutional limits (except for Gilbert's)

- Aspartate aminotransferase (AST) (serum glutamic oxalo-acetic transaminase
[SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
=< 2.5 X institutional upper limit of normal

- Creatinine glomerular filtration rate (GFR) (calculated or measured) > 50 mL/min

- Hemoglobin >= 9 g/dL

- Women of child-bearing potential and men must agree to use adequate contraception
(hormonal or barrier method of birth control; abstinence) prior to study entry and
for the duration of study participation

- Should a woman become pregnant or suspect she is pregnant while she or her partner is
participating in this study, she should inform her treating physician immediately

- Men treated or enrolled on this protocol must also agree to use adequate
contraception prior to the study, for the duration of study participation, and 4
months after completion of TRC105 or bevacizumab administration

- Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

- Patients who have had systemic biologic therapy or radiotherapy within 2 weeks prior
to entering the study or those who have not recovered from adverse events related to
their prior therapy

- Patients who have previously been treated with bevacizumab

- Patients who have previously been treated with TRC105

- Patients who are receiving any other investigational agents

- Known central nervous system (CNS) disease except for treated brain metastasis;
treated brain metastases are defined as having no ongoing requirement for steroids
and no evidence of progression or hemorrhage after treatment for at least 3 months,
as ascertained by clinical examination and brain imaging (MRI or CT) (stable dose of
anticonvulsants are allowed); treatment for brain metastases may include whole brain
radiotherapy (WBRT), radiosurgery (RS; Gamma Knife, linear accelerator [LINAC], or
equivalent) or a combination as deemed appropriate by the treating physician;
patients with CNS metastases treated by neurosurgical resection or brain biopsy
performed within 3 months prior to Day 1 will be excluded

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to TRC105 or bevacizumab

- Patients on full-dose anticoagulation will be excluded due to the risk of bleeding;
antiplatelet therapy will not be exclusionary

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, unhealed wound, gastrointestinal fistula, symptomatic congestive heart
failure, unstable angina pectoris, myocardial infarction, cerebrovascular accident

- Pregnant women are excluded from this study; TRC105 and bevacizumab are
anti-angiogenic agents with significant potential for teratogenic or abortifacient
effects; because there is an unknown but potential risk for adverse events in nursing
infants secondary to treatment of the mother with TRC105 and bevacizumab,
breastfeeding should be discontinued if the mother wishes to participate in the study

- Patients with a history of bleeding diathesis or inherited coagulopathy are excluded
due to the risk of bleeding and thrombosis associated with bevacizumab; in addition,
those with a history of deep vein thrombosis (DVT) or pulmonary embolus within 1 year
and still requiring active anticoagulation will be excluded; those with a more remote
history of DVT or pulmonary embolus may be eligible but the risk of recurrent
thrombosis should be considered

- Patients with history of hereditary hemorrhagic telangiectasis (HHT-1 and HHT-2)

- Serious or non-healing wound, ulcer, or bone fracture OR history of abdominal
fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months
prior to day 1

- Invasive procedures defined as follows:

- Major surgical procedure, open biopsy or significant traumatic injury within 28
days prior to Day 1 therapy

- Anticipation of need for major surgical procedures during the course of the

- Core biopsy within 7 days prior to Day 1 therapy

- Patients with clinically significant cardiovascular disease are excluded:

- Inadequately controlled hypertension (HTN) (systolic blood pressure [SBP] >
160mmHg and/or diastolic blood pressure [DBP] > 90 mmHg despite antihypertensive

- History of cardiovascular accident (CVA) within 6 months

- Myocardial infarction or unstable angina within 6 months

- New York heart association grade II or greater congestive heart failure

- Serious and inadequately controlled cardiac arrhythmia

- Significant vascular disease (e.g. aortic aneurysm, history of aortic

- Clinically significant peripheral vascular disease

- Patients with known hypersensitivity to Chinese hamster ovary cell products or other
recombinant human antibodies

- Patients with psychiatric illness/social situations that would limit compliance with
study requirements will be excluded

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Progression-free survival (PFS)

Outcome Description:

Planning is based on the supposition of 12-week PFS of 61% on the control arm and 78% on the combination arm.

Outcome Time Frame:

The duration of time from start of treatment to time of progression or death, assessed at 12 weeks

Safety Issue:


Principal Investigator

Tanya Dorff

Investigator Role:

Principal Investigator

Investigator Affiliation:

Beckman Research Institute


United States: Food and Drug Administration

Study ID:




Start Date:

November 2012

Completion Date:

Related Keywords:

  • Clear Cell Renal Cell Carcinoma
  • Recurrent Renal Cell Cancer
  • Stage IV Renal Cell Cancer
  • Type 1 Papillary Renal Cell Carcinoma
  • Type 2 Papillary Renal Cell Carcinoma
  • Carcinoma
  • Carcinoma, Renal Cell



Mayo Clinic Rochester, Minnesota  55905
University of Iowa Hospitals and Clinics Iowa City, Iowa  52242
Washington University School of Medicine Saint Louis, Missouri  63110
University of Pittsburgh Cancer Institute Pittsburgh, Pennsylvania  15213
City of Hope Duarte, California  91010
Wayne State University Detroit, Michigan  48202
USC Norris Comprehensive Cancer Center Los Angeles, California  90089
Metro-Minnesota CCOP St. Louis Park, Minnesota  
UC Davis Comprehensive Cancer Center Sacramento, California  95817
M D Anderson Cancer Center Houston, Texas  77030
University of Southern California Los Angeles, California  90033
Penn State Milton S Hershey Medical Center Hershey, Pennsylvania  17033
City of Hope Medical Group Inc Pasadena, California  91105
University of Miami Miller School of Medicine-Sylvester Cancer Center Miami, Florida  33136
University of Colorado at Denver Health Sciences Center Denver, Colorado  80045